Francois Mach Articles

Will the advent of oral PCSK9 inhibitors change the clinical scenery in ASCVD? Setting the scene

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Professor François Mach   Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or…

Low LDL-C and cognitive function: Benefit or harm?

Reports from the 8th Expert Meeting of PCSK9 Forum Professor Francois Mach

How do you explain the different mortality results in ODYSSEY Outcomes versus FOURIER?

PCSK9 inhibition and neurocognitive effects:Weighing up the evidence

Whether lowering LDL cholesterol levels has detrimental effects on cognitive function has long been a concern with statins (1). Recently, attention has also focused on the PCSK9 inhibitors.  Professor François Mach (Geneva University Hospitals, Switzerland) discusses what is known from the latest trials. Evidence from…

EBBINGHAUS counters claim of neurocognitive effects with PCSK9 inhibition

Ebbinghaus was a pioneer of memory research. One of his key contributions was the forgetting curve, which describes the exponential loss of learned information. It is therefore fitting that a trial bearing his name has shown that very low LDL cholesterol levels on PCSK9 monoclonal…

Prof Francois Mach: How will FOURIER impact guidelines

Prof Francois Mach discusses EBBINGHAUS

Outcomes data are critical

The Healthcare System Perspective in Europe: Francois Mach, University of Geneva, Switzerland